The prognostic significance of bone marrow metastases in small cell lung cancer patients

Lung Cancer. 1993 Dec;10(3-4):239-45. doi: 10.1016/0169-5002(93)90184-y.

Abstract

One-hundred forty-six SCLC patients were classified as localised (56) or extensive (90) using chest X-ray, bronchoscopy, brain CT, bone scintigraphy, ultrasonography of the abdomen and bilateral bone marrow trephine biopsy. Bone marrow metastases were found in 28 cases. Patients with bone marrow metastases had significantly shorter time to progression (median 20 weeks) and significantly shorter survival time (median 31 weeks) than other patients with extensive disease (medians 30 and 46 weeks). Patients with bone marrow involvement had significantly more often metastases in three or more organs than others with extensive disease. The negative prognostic significance of bone marrow involvement was however independent of the negative prognostic significance of the number of organs with metastases.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow / pathology*
  • Carcinoma, Small Cell / pathology
  • Carcinoma, Small Cell / secondary*
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Lung Neoplasms / pathology*
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoplasm Metastasis
  • Prognosis
  • Proportional Hazards Models
  • Survival Analysis

Substances

  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Methotrexate